IPP Bureau
Marksans Pharma Q1 FY25 revenue up 18%
By IPP Bureau - August 14, 2024
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
NHA and MUHS sign MoU to drive digital health education
By IPP Bureau - August 14, 2024
The partnership marks a significant milestone in integrating digital health education into medical curricula
Wanbury appoints Prakash Venkatraman as President of API Business
By IPP Bureau - August 14, 2024
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA
By IPP Bureau - August 14, 2024
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth
By IPP Bureau - August 13, 2024
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
HealthCRED secures US$ 1.2 million in seed funding
By IPP Bureau - August 13, 2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Pfizer announces results of ABRYSVO for RSV in immunocompromised adults
By IPP Bureau - August 13, 2024
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Alembic receives USFDA final approval for Dabigatran Etexilate Capsules, 110 mg
By IPP Bureau - August 13, 2024
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland
By IPP Bureau - August 13, 2024
This project is supported by the Irish Government through IDA Ireland
Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
By IPP Bureau - August 13, 2024
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
By IPP Bureau - August 13, 2024
Morepen Labs successfully raised Rs. 200 Crore through QIP
Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
By IPP Bureau - August 12, 2024
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Novo Nordisk's H1 sales increased by 24% in Danish kroner
By IPP Bureau - August 12, 2024
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Wockhardt Q1 FY25 revenue up 14%
By IPP Bureau - August 12, 2024
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr
By IPP Bureau - August 12, 2024
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
